⨯

  • 07 Dec 22

NIOX (NIOX) - Q&A with Harwood Capital CEO, Christopher Mills

NIOX (NIOX) - Q&A with Harwood Capital CEO, Christopher Mills

NIOX Group Plc | CSSPF | 0 -0.42 (0.0%)
Follow Company Follow Company

    • 7 views

 

Enjoying this article?

Get a £25 credit by sharing with your friends and colleagues via the share buttons below. Each new subscriber gets a 10% discount and you get a free month off your bill every time.


Don't worry, if you're a Lite-Access/Free user we save all your credits for the day you decide to fully subscribe.


 

Circassia (CIR) - Vox Markets fund manager interview with Christopher Mills

Companies: NIOX Group Plc

NetScientific changes "really paying off"

Companies: NetScientific plc

Circassia Pharmaceuticals' commercial development 'accelerating significantly'

Companies: NIOX Group Plc

Creo Medical Group "really pleased" with first human trial of lung lesion treatment

Companies: Creo Medical Group Plc

Investor Update: Circassia boosts first-half revenues by 40%

Companies: NIOX Group Plc

Creo Medical Group "gaining a level of acceptance" in endoscopy

Companies: Creo Medical Group Plc

Copyright © 2023 Research Tree | All Rights Reserved. | Terms of Service and Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top